Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial of Tremelimumab in Patients With Metastatic Urothelial Cancer Previously Treated With PD-1/PD-L1 Blockade

NCT03557918 is registered in ClinicalTrials.gov with Matthew Galsky as lead sponsor.

NCT NCT03557918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03557918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial of Tremelimumab in Patients With Metastatic Urothelial Cancer Previously Treated With PD-1/PD-L1 Blockade
Lead sponsor
Matthew Galsky
Phase
Phase 2
Overall status
Completed
Start date
November 12, 2018
Completion date
June 7, 2023
Enrollment
26 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial carcinoma